The patient has received any investigational therapy within  weeks of enrollment
Investigational Drugs: Subjects who have received another investigational drug within the last  days are excluded from participation.
Other investigational drugs or investigational therapy if the patient is currently taking those drugs/therapy, or if they have received the drugs/therapy within  month.
Subjects taking other investigational drugs or drugs of abuse within  days of entry into this study.
Patients receiving other investigational immunotherapy or anti-myeloma drugs within  days before enrollment.
Patient is receiving other investigational drugs
Have received other investigational drugs within  days of enrollment.
Received any investigational drugs within the  days prior to CIML NK cell infusion date
Received investigational drugs within the  days before st dose of study drug
Investigational drugs: subjects must not have received an investigational drug within  weeks
Patient has received other investigational drugs with  days before enrollment
Received any investigational drugs within the  days prior to the first day of transplant conditioning
Patients who have received other investigational drugs within  days prior to screening
Exposure to other investigational drugs within  weeks before enrollment
Patients who are receiving other investigational drugs  or fewer days before enrollment
Have received other investigational drugs within  days prior to enrollment
Patient has received other investigational drugs with  days before enrollment
Patients who have received other investigational drugs within  days of Viralym-A infusion.
Patient has received other investigational drugs within  days before enrollment
Investigational Drugs: Subjects who have received another investigational drug within the last  days are excluded from participation.
Treatment with other investigational drugs within  months of study entry
Patient has received other investigational drugs within  weeks before enrollment
Received any investigational drugs within the  days prior to the first dose of fludarabine
Exposure to other investigational drugs within  weeks before enrollment
Patient has received other investigational drugs within  weeks before study registration
Subjects who have received any investigational drugs or devices within  weeks before the first day of study treatment (CD).
Received any investigational drugs within the  days before st dose of fludarabine
Have received either of the study drugs
Participants who are receiving, or have received, any other investigational drugs or devices within the  weeks prior to the first dose of study medications
Patients who have received hepatotoxic drugs less than  days prior to enrollment
Received investigational drugs within the  days of study registration
Patient has received other investigational drugs with  days before treatment of treatment with bortezomib + rituximab
Patient has received other investigational drugs with  days before enrollment
Currently receiving or has received any investigational drugs within the  days prior to the first dose of study drug (day -)
Subjects who have received investigational drugs =<  weeks prior to registration
Patients on other investigational drugs while on study will be excluded
Subject has received other investigational drugs within  days prior to first dose of study drug.
Other investigational drugs within  weeks prior to enrollment, unless cleared by the Principal Investigator
Investigational drugs: subjects must not have received an investigational drug within  weeks
Patient has received other investigational drugs with  days before enrollment
Patient has received other investigational drugs with  days before enrollment
Taking other investigational drugs
Patient has received other investigational drugs within  weeks before study registration
Received investigational drugs within the  days before enrollment
Received any investigational drugs within the  days before st dose of fludarabine
Patient has received other investigational drugs within  days prior to enrollment
Patient has received other investigational drugs with  days before enrollment
Patient has received other investigational drugs with  days before enrollment
Patient has received other investigational drugs with  days before enrollment.
Patient has not received other investigational drugs with  days before enrollment
Patient has received other investigational drugs or chemotherapy within  days or approved anti-myeloma therapy within  days.
Patient has received other investigational drugs with  days before enrollment
Patient has received other investigational drugs within  week before enrollment.
Patients who have received other investigational drugs within  days of Viralym-C infusion
Patient has received other investigational drugs with  days before enrollment
Patient has received other investigational drugs with  days before enrollment
Patient has received other investigational drugs within  days of treatment initiation
Patient has received other investigational drugs within  days before enrollment or who have not recovered from side effects of those therapies
Have received other investigational drugs within  days prior to enrollment
Other investigational drugs within  weeks prior to enrollment, unless cleared by the principal investigator
Currently receiving or has received any investigational drugs within the  days prior to the first dose of the conditioning regimen
Has received investigational drugs suspected to cause peripheral neuropathy; no concurrent investigational drugs may be used
Investigational drugs: must not be receiving other investigational (from other studies) drugs at time of enrollment and must not be planning to take other investigational drugs during DLT period
Other investigational drugs
